SEC Form 4 Reporting Owner · CIK 0001595855
Opaleye Management Inc.
10%+ at Grace Therapeutics Inc · 10%+ at Alpha Cognition Inc · 10%+ at Sol-Gel Technologies Ltd · +6 more
Bought (12 mo)
+$20.1M
Sold (12 mo)
−$17.6M
Form 4 Filings
168
Companies
9
Filing Activity
2026-11-19
first filed 2021-06-22
Trading record
Open-market buys
+$52.3M
147 filings
Open-market sales
−$22.4M
20 filings
Sales under a 10b5-1 plan
0%
0 of 20 sale filings · 1 undisclosed
Companies
| Company | Role | Filings | Bought | Sold | Net | Holding after latest filing |
|---|---|---|---|---|---|---|
| GRCEGrace Therapeutics Insider trading | 10%+ | 11 | 354,521 | — | +354,521 | 3,102,904 2026-11-19 |
| ACOGAlpha Cognition Insider trading | 10%+ | 25 | 1,198,884 | — | +1,198,884 | 3,391,984 2026-10-26 |
| SLGLSol-Gel Insider trading | 10%+ | 24 | 197,444 | — | +197,444 | 555,000 2026-09-14 |
| ETONEton Pharmaceuticals Insider trading | 10%+ | 3 | 7,930 | 155,000 | −147,070 | 2,705,000 2026-07-16 |
| SNWVSANUWAVE Insider trading | 10%+ | 6 | 37,133 | 122,698 | −85,565 | 858,569 2026-05-04 |
| HROWHarrow Insider trading | 10%+ | 25 | 924,584 | 308,572 | +616,012 | 3,681,428 2026-03-05 |
| CDXSCodexis Insider trading | 10%+ | 26 | 5,263,930.077 | 2,660,011 | +2,603,919.077 | 10,134,989 2025-12-01 |
| TCONTracon Pharmaceuticals Insider trading | 10%+ | 30 | 1,900,958.304 | 4,765,547 | −2,864,588.696 | 0 2023-11-14 |
| TELATELA Bio Insider trading | Other | 18 | 511,475 | — | +511,475 | 2,072,813 2023-04-20 |
Common-stock shares bought and sold on the open market, as reported on Form 4. The holding is what the latest filing at each company reported owning after its transactions.
Also files as
13F Institutional investment manager · Opaleye Management Inc. 13F holdings
13D/G Beneficial owner of 5% or more · 9 open stakes (9 reported closed)
| Company | Schedule | % of class | Filed |
|---|---|---|---|
| Eton Pharmaceuticals | 13G | 8.5% | 2026-11-06 |
| Sol-Gel | 13G | 16.5% | 2026-11-06 |
| Harrow | 13G | 5.6% | 2026-11-06 |
| Gossamer Bio | 13G | 7.0% | 2026-11-06 |
| Grace Therapeutics | 13G | 13.1% | 2026-08-07 |